Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Has Average Target Price of $31.91

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus rating of “Hold” from the twelve research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $31.91.

SNN has been the topic of several recent research reports. Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Bank of America cut Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a report on Tuesday, September 8th. Zacks Research upgraded Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 8th. Weiss Ratings raised Smith & Nephew SNATS from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 4th. Finally, Wall Street Zen upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a report on Sunday, September 13th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several hedge funds and other institutional investors have recently bought and sold shares of SNN. Equity Investment Corp increased its stake in Smith & Nephew SNATS by 3.9% in the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 285 shares during the last quarter. Cary Street Partners Financial LLC lifted its position in shares of Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after buying an additional 365 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock worth $74,000 after buying an additional 387 shares during the last quarter. Clearstead Trust LLC acquired a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at $25,000. Finally, BKM Wealth Management LLC boosted its holdings in shares of Smith & Nephew SNATS by 2.5% in the 1st quarter. BKM Wealth Management LLC now owns 18,462 shares of the medical equipment provider’s stock valued at $587,000 after buying an additional 451 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Down 0.7%

Shares of NYSE SNN opened at $26.64 on Tuesday. Smith & Nephew SNATS has a 12-month low of $26.52 and a 12-month high of $37.51. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $29.40 and a 200 day moving average of $30.60.

Smith & Nephew SNATS Dividend Announcement

The company also recently declared a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be given a dividend of $0.3120 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a dividend yield of 205.0%.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.